Published in Diabetes on May 05, 2008
Mechanisms underlying skeletal muscle insulin resistance induced by fatty acids: importance of the mitochondrial function. Lipids Health Dis (2012) 1.32
Inducible nitric oxide synthase induction underlies lipid-induced hepatic insulin resistance in mice: potential role of tyrosine nitration of insulin signaling proteins. Diabetes (2010) 1.14
Receptors for tumor necrosis factor-alpha play a protective role against obesity and alter adipose tissue macrophage status. Endocrinology (2009) 1.13
Inducible nitric oxide synthase deficiency in myeloid cells does not prevent diet-induced insulin resistance. Mol Endocrinol (2010) 1.02
Transcription factors Krüppel-like factor 6 and peroxisome proliferator-activated receptor-{gamma} mediate high glucose-induced thioredoxin-interacting protein. Am J Pathol (2009) 0.96
Mitochondrial dysfunction and activation of iNOS are responsible for the palmitate-induced decrease in adiponectin synthesis in 3T3L1 adipocytes. Exp Mol Med (2012) 0.85
Peroxynitrite-driven mechanisms in diabetes and insulin resistance - the latest advances. Curr Med Chem (2011) 0.79
Inhibitory effect of baicalin on iNOS and NO expression in intestinal mucosa of rats with acute endotoxemia. PLoS One (2013) 0.78
Obesity and insulin resistance: an abridged molecular correlation. Lipid Insights (2013) 0.78
Silencing CCR2 in Macrophages Alleviates Adipose Tissue Inflammation and the Associated Metabolic Syndrome in Dietary Obese Mice. Mol Ther Nucleic Acids (2016) 0.75
Altered glucose and lipid homeostasis in liver and adipose tissue pre-dispose inducible NOS knockout mice to insulin resistance. Sci Rep (2017) 0.75
Voluntary Exercise Can Ameliorate Insulin Resistance by Reducing iNOS-Mediated S-Nitrosylation of Akt in the Liver in Obese Rats. PLoS One (2015) 0.75
Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med (2002) 14.15
AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab (2005) 13.91
The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature (1998) 13.58
An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem (1995) 13.34
Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science (2001) 11.22
A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem (1995) 9.72
Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest (1995) 9.59
Thiazolidinediones. N Engl J Med (2004) 9.42
Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A (2000) 5.65
Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem (2003) 5.40
Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA (2007) 5.02
NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia (1997) 4.88
Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology (1994) 4.67
Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity. J Biol Chem (2002) 4.60
Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma. Science (1996) 4.50
Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci U S A (2002) 4.40
Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. J Biol Chem (2005) 4.32
Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone. J Clin Invest (2004) 4.16
Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med (2005) 4.14
Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem (2003) 4.08
Muscle-specific Pparg deletion causes insulin resistance. Nat Med (2003) 3.93
Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem (2003) 3.90
Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. J Biol Chem (1997) 3.19
Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res (2004) 3.16
Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle. Nat Med (2001) 3.14
A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology (2003) 3.04
Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res (2000) 3.02
Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest (1997) 2.73
Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. Proc Natl Acad Sci U S A (2005) 2.56
Role of nitric oxide in obesity-induced beta cell disease. J Clin Invest (1997) 2.45
Adiponectin differentially regulates cytokines in porcine macrophages. Biochem Biophys Res Commun (2004) 2.32
Lipid metabolome-wide effects of the PPARgamma agonist rosiglitazone. J Lipid Res (2002) 2.30
Expression of nitric oxide synthase in skeletal muscle: a novel role for nitric oxide as a modulator of insulin action. Diabetes (1997) 1.72
Genetic modulation of PPARgamma phosphorylation regulates insulin sensitivity. Dev Cell (2003) 1.60
Phosphorylation-activity relationships of AMPK and acetyl-CoA carboxylase in muscle. J Appl Physiol (1985) (2002) 1.56
Role of PPARs in the regulation of obesity-related insulin sensitivity and inflammation. Int J Obes Relat Metab Disord (2003) 1.53
Inhibition of inducible nitric-oxide synthase by activators of AMP-activated protein kinase: a new mechanism of action of insulin-sensitizing drugs. J Biol Chem (2004) 1.38
A role for iNOS in fasting hyperglycemia and impaired insulin signaling in the liver of obese diabetic mice. Diabetes (2005) 1.37
Tissue-specific effects of rosiglitazone and exercise in the treatment of lipid-induced insulin resistance. Diabetes (2007) 1.32
Inflammation and nitric oxide production in skeletal muscle of type 2 diabetic patients. J Endocrinol (2004) 1.31
Inducible nitric-oxide synthase and NO donor induce insulin receptor substrate-1 degradation in skeletal muscle cells. J Biol Chem (2005) 1.30
Hormone-sensitive lipase has a role in lipid signaling for insulin secretion but is nonessential for the incretin action of glucagon-like peptide 1. Diabetes (2004) 1.29
Inducible nitric oxide synthase has divergent effects on vascular and metabolic function in obesity. Diabetes (2005) 1.21
Differential effects of rosiglitazone on skeletal muscle and liver insulin resistance in A-ZIP/F-1 fatless mice. Diabetes (2003) 1.19
Nitration of PPARgamma inhibits ligand-dependent translocation into the nucleus in a macrophage-like cell line, RAW 264. FEBS Lett (2002) 1.19
Activation of peroxisome proliferator-activated receptor gamma does not inhibit IL-6 or TNF-alpha responses of macrophages to lipopolysaccharide in vitro or in vivo. J Immunol (2000) 1.18
Potentiation of insulin signaling in tissues of Zucker obese rats after acute and long-term treatment with PPARgamma agonists. Diabetes (2002) 1.16
Cytokines modulate glucose transport in skeletal muscle by inducing the expression of inducible nitric oxide synthase. Biochem J (1997) 1.12
Adiponectin: a relevant player in PPARgamma-agonist-mediated improvements in hepatic insulin sensitivity? Int J Obes (Lond) (2005) 1.12
TNF-alpha-induced insulin resistance in vivo and its prevention by troglitazone. Diabetes (1997) 1.06
Regulation of the nitric oxide system in human adipose tissue. J Lipid Res (2004) 1.02
Ragaglitazar: a novel PPAR alpha PPAR gamma agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Br J Pharmacol (2003) 0.99
Peroxisome proliferator-activated receptor gamma and the control of adipogenesis. Curr Opin Lipidol (1997) 0.92
High-performance liquid chromatographic method for the determination of pioglitazone in human plasma using ultraviolet detection and its application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 0.84
Effects of insulin-sensitising agents in mice with hepatic insulin resistance. Diabetologia (2004) 0.83
Adiponectin mRNA levels in parametrial adipose tissue and serum adiponectin levels are reduced in mice during late pregnancy. Horm Metab Res (2004) 0.81
A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature (2007) 35.08
Adipose tissue, inflammation, and cardiovascular disease. Circ Res (2005) 8.72
Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest (2007) 8.71
Adipose tissue remodeling and obesity. J Clin Invest (2011) 6.12
DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell (2009) 5.97
Genetic variant near IRS1 is associated with type 2 diabetes, insulin resistance and hyperinsulinemia. Nat Genet (2009) 5.43
Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem (2003) 5.40
Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med (2010) 4.96
Exercise-induced BCL2-regulated autophagy is required for muscle glucose homeostasis. Nature (2012) 4.84
Metabolic dysregulation and adipose tissue fibrosis: role of collagen VI. Mol Cell Biol (2008) 4.75
ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab (2002) 4.64
Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity. J Biol Chem (2002) 4.60
Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. J Biol Chem (2005) 4.32
Minireview: The adipocyte--at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology (2003) 4.28
Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes (2007) 4.28
Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab (2010) 4.08
Hypoxia-inducible factor 1alpha induces fibrosis and insulin resistance in white adipose tissue. Mol Cell Biol (2009) 3.96
Tracking adipogenesis during white adipose tissue development, expansion and regeneration. Nat Med (2013) 3.86
mTORC1 controls fasting-induced ketogenesis and its modulation by ageing. Nature (2010) 3.81
Caveolin-1-deficient mice are lean, resistant to diet-induced obesity, and show hypertriglyceridemia with adipocyte abnormalities. J Biol Chem (2001) 3.54
Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet (2011) 3.50
Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance. Endocrinology (2004) 3.50
Adiponectin acts in the brain to decrease body weight. Nat Med (2004) 3.47
Identification of IRS-1 Ser-1101 as a target of S6K1 in nutrient- and obesity-induced insulin resistance. Proc Natl Acad Sci U S A (2007) 3.32
The hyperglycemia-induced inflammatory response in adipocytes: the role of reactive oxygen species. J Biol Chem (2004) 3.31
Adipose tissue-derived factors: impact on health and disease. Endocr Rev (2006) 3.16
Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. J Clin Invest (2003) 3.11
A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology (2003) 3.04
Lipid homeostasis, lipotoxicity and the metabolic syndrome. Biochim Biophys Acta (2009) 2.84
Fat apoptosis through targeted activation of caspase 8: a new mouse model of inducible and reversible lipoatrophy. Nat Med (2005) 2.78
Saturated fatty acids synergize with elevated glucose to cause pancreatic beta-cell death. Endocrinology (2003) 2.76
Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology (2002) 2.72
JNK1 but not JNK2 promotes the development of steatohepatitis in mice. Hepatology (2006) 2.70
Lipid-induced insulin resistance mediated by the proinflammatory receptor TLR4 requires saturated fatty acid-induced ceramide biosynthesis in mice. J Clin Invest (2011) 2.68
Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue. Diabetes (2010) 2.65
An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice. Cell Metab (2013) 2.62
Direct insulin and leptin action on pro-opiomelanocortin neurons is required for normal glucose homeostasis and fertility. Cell Metab (2010) 2.58
Gluttony, sloth and the metabolic syndrome: a roadmap to lipotoxicity. Trends Endocrinol Metab (2010) 2.58
Overactivation of S6 kinase 1 as a cause of human insulin resistance during increased amino acid availability. Diabetes (2005) 2.55
AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome. Nat Rev Drug Discov (2004) 2.46
AMPK, insulin resistance, and the metabolic syndrome. J Clin Invest (2013) 2.44
Sexual differentiation, pregnancy, calorie restriction, and aging affect the adipocyte-specific secretory protein adiponectin. Diabetes (2003) 2.40
Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. J Clin Invest (2005) 2.38
Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. Role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. J Biol Chem (2004) 2.37
Secretion of the adipocyte-specific secretory protein adiponectin critically depends on thiol-mediated protein retention. Mol Cell Biol (2007) 2.27
Adipocyte-secreted factors synergistically promote mammary tumorigenesis through induction of anti-apoptotic transcriptional programs and proto-oncogene stabilization. Oncogene (2003) 2.27
Role of caveolin-1 in the modulation of lipolysis and lipid droplet formation. Diabetes (2004) 2.26
Dichotomous effects of VEGF-A on adipose tissue dysfunction. Proc Natl Acad Sci U S A (2012) 2.24
Fatty acid signaling in the beta-cell and insulin secretion. Diabetes (2006) 2.22
Cyclin D1 repression of peroxisome proliferator-activated receptor gamma expression and transactivation. Mol Cell Biol (2003) 2.22
The adipocyte as an endocrine cell. Endocrinol Metab Clin North Am (2008) 2.20
Consuming fructose-sweetened beverages increases body adiposity in mice. Obes Res (2005) 2.18
Adipokines as novel biomarkers and regulators of the metabolic syndrome. Ann N Y Acad Sci (2010) 2.16
Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes (2003) 2.16
A haplotype at the adiponectin locus is associated with obesity and other features of the insulin resistance syndrome. Diabetes (2002) 2.15
MitoNEET-driven alterations in adipocyte mitochondrial activity reveal a crucial adaptive process that preserves insulin sensitivity in obesity. Nat Med (2012) 2.13
Coordinate regulation of malonyl-CoA decarboxylase, sn-glycerol-3-phosphate acyltransferase, and acetyl-CoA carboxylase by AMP-activated protein kinase in rat tissues in response to exercise. J Biol Chem (2002) 2.11
Role for activating transcription factor 3 in stress-induced beta-cell apoptosis. Mol Cell Biol (2004) 2.10
Fibrosis and adipose tissue dysfunction. Cell Metab (2013) 2.07
Caveolin-1-deficient mice show insulin resistance and defective insulin receptor protein expression in adipose tissue. Am J Physiol Cell Physiol (2003) 2.06
Role of dietary proteins and amino acids in the pathogenesis of insulin resistance. Annu Rev Nutr (2007) 2.03
C/EBPalpha and the corepressors CtBP1 and CtBP2 regulate repression of select visceral white adipose genes during induction of the brown phenotype in white adipocytes by peroxisome proliferator-activated receptor gamma agonists. Mol Cell Biol (2009) 1.98
Plasma adiponectin complexes have distinct biochemical characteristics. Endocrinology (2008) 1.94
Targeted deletion of adipocytes by apoptosis leads to adipose tissue recruitment of alternatively activated M2 macrophages. Endocrinology (2011) 1.94
Progressive loss of beta-cell function leads to worsening glucose tolerance in first-degree relatives of subjects with type 2 diabetes. Diabetes Care (2007) 1.91
Adiponectin: systemic contributor to insulin sensitivity. Curr Diab Rep (2003) 1.90
The transcriptional response of the islet to pregnancy in mice. Mol Endocrinol (2009) 1.89
Adiponectin in health and disease: evaluation of adiponectin-targeted drug development strategies. Trends Pharmacol Sci (2009) 1.89
Myofibroblasts in murine cutaneous fibrosis originate from adiponectin-positive intradermal progenitors. Arthritis Rheumatol (2015) 1.85
Role of resistin in diet-induced hepatic insulin resistance. J Clin Invest (2004) 1.83
The adipocyte as an important target cell for Trypanosoma cruzi infection. J Biol Chem (2005) 1.82
Disulfide-dependent multimeric assembly of resistin family hormones. Science (2004) 1.76
Diabetes and apoptosis: lipotoxicity. Apoptosis (2009) 1.75
Mechanisms of obesity and related pathologies: the macro- and microcirculation of adipose tissue. FEBS J (2009) 1.73
Enhanced metabolic flexibility associated with elevated adiponectin levels. Am J Pathol (2010) 1.72
Identification and characterization of a promoter cassette conferring adipocyte-specific gene expression. Endocrinology (2010) 1.71
Activation of the mammalian target of rapamycin pathway acutely inhibits insulin signaling to Akt and glucose transport in 3T3-L1 and human adipocytes. Endocrinology (2004) 1.71
Within-individual stability of obesity-related biomarkers among women. Cancer Epidemiol Biomarkers Prev (2007) 1.67
Adipocyte-derived factors potentiate nutrient-induced production of plasminogen activator inhibitor-1 by macrophages. Sci Transl Med (2010) 1.67
The fatty acid receptor GPR40 plays a role in insulin secretion in vivo after high-fat feeding. Diabetes (2008) 1.66
Role of caveolin and caveolae in insulin signaling and diabetes. Am J Physiol Endocrinol Metab (2003) 1.66
Beta-cell failure in diet-induced obese mice stratified according to body weight gain: secretory dysfunction and altered islet lipid metabolism without steatosis or reduced beta-cell mass. Diabetes (2010) 1.66
Paracrine and endocrine effects of adipose tissue on cancer development and progression. Endocr Rev (2011) 1.65
Systemic fate of the adipocyte-derived factor adiponectin. Diabetes (2009) 1.65
Selective downregulation of the high molecular weight form of adiponectin in hyperinsulinemia and in type 2 diabetes: differential regulation from nondiabetic subjects. Diabetes (2007) 1.63
ACDC/adiponectin polymorphisms are associated with severe childhood and adult obesity. Diabetes (2006) 1.62